Why the study?
Does irbesartan improve insulin signaling and reduce hepatic steatosis in obese Zucker rats?
Population
Obese Zucker rats (OZR), an animal model of human metabolic syndrome, and lean Zucker rats
Comparison
Irbesartan 50 mg/kg a day for 6 months vs Untreated obese Zucker rats and lean Zucker rats
Design
Preclinical
Follow-up
6 months
Authors
Loading...
Extends preclinical evidence for irbesartan in metabolic syndrome models; leaves open translation to human therapy.
Does irbesartan improve insulin signaling and reduce hepatic steatosis in obese Zucker rats?
Long-term selective angiotensin II blockade by irbesartan improves hepatic insulin signaling and reduces hepatic steatosis in an animal model of metabolic syndrome.
Muñoz et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: